Kim Moran, SVP, head of U.S. Rare Diseases, discusses new treatments being approved by the FDA to combat myasthenia gravis.
Transcription
Hi, I’m Kim Moran. I am the Head of U.S. Rare Disease for the US, for UCB. I get to help people living with rare diseases across the US. My focus right now is on myasthenia gravis and mitochondrial disease. I have had the honor of having two FDA approvals for generalized myasthenia gravis US this year, with two novel medications to really help the unmet need.
I also get to leverage our strategic approach of being patient first and digital first. We’re able to first understand patients, their deep journey, knowing that each rare patient is different, especially those living with myasthenia gravis. Then how we can use digital technology to find patients where they are and how we can meet their unmet needs.
ZILBRYSQ, which garnered its FDA approval last month, is approved for generalized myasthenia gravis. For those that are AChR positive, that means anti-acetylcholine receptor antibody-positive patients. What’s unique about ZILBRYSQ? It is the first and only once daily subcutaneous C-5 complement inhibitor.
That means patients can self-administer this once daily medication. All other targeted therapies for generalized myasthenia gravis generally mean some type of infusion or going to a brick-and-mortar doctor’s office. Well, what’s super exciting is we can support the broad needs of both patients and healthcare professionals. What we see is that you need to tailor solutions to problems.
Each patient is different. Being able to have not one, but two types of different therapies, different mechanisms of action, different mode of administration allows for an individualized treatment approach for patients with generalized myasthenia gravis.
To learn more about Myasthenia Gravis: https://checkrare.com/diseases/autoimmune-auto-inflammatory-disorders/
